Aim: To assess the safety of perioperative use of Low Molecular Weight Heparin (LMWH) in the setting of breast reduction surgery.
Methods: Retrospective assessment of the reoperation rate due to hematoma formation for breast reductions performed under a regimen of preoperative and postoperative administration of LMWH during a 10 year period.
Results: A total of 720 patients (1358 breasts) received preoperative and postoperative treatment with LMWH. Reoperation due to hematoma formation was required for 37 breasts in 37 patients (5.1% of patients and 2.7% of breasts). Eight patients (1.1%) required transfusion. No patient or operative factors were associated with the need for reoperation. There were no documented cases of deep vein thrombosis or VTE.
Conclusion: Use of a pre and postoperative LMWH administration as a VTE prophylaxis regimen is associated with a reoperation rate for hematoma that is similar to that reported in the literature using other VTE prophylaxis regimens.
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